Stock MGNK MOLOGEN AG
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Mologen AG Xetra

Equities

MGNK

DE000A2LQ900

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Mologen AG Announces Updates on Phase III IMPALA Study; Provides Earnings Guidance for the Full Year 2019
CI
Mologen AG Announces Management Changes
CI
Mologen AG Announces Management Changes
CI
Mariola Soehngen Not to Renew Her Position as Member and Chief Executive Officer on the Board of Directors of Mologen AG Which Expires on 31 October 2018
CI
Mologen Reports Earnings Results for the Six Months of 2016; Provides Earnings Guidance for the Full Year of 2016
CI
Mologen AG Announces Progress in Clinical Studies; Announces Earnings Results for the First Quarter of 2016; Confirms Earnings Guidance for the Year 2016
CI
Mologen AG Reports Earnings Results for the Year 2015
CI
MOLOGEN AG Appoints Walter Miller as Member of the Executive Board and Chief Financial Officer with Effect from April 1, 2016
CI
Mologen AG Announces Extension of TEACH Study Based on Supportive First Study Results
CI
Mologen AG Supports Development Strategy of lefitolimod (MGN1703)
CI
MOLOGEN AG and the University of Texas MD Anderson Cancer Center Enter into Collaboration Agreement Relating to Phase I trial with MOLOGEN’s Immunomodulator Lefitolimod in Combination with the Immunotherapy Yervoy® in Patients with Advanced Solid Malignancies
CI
MOLOGEN AG Reaffirms Earnings Guidance Financial Year 2015
CI
Mologen AG(XTRA:MGN) dropped from S&P Global BMI Index
CI
Mologen AG Reports Earnings Results for the First Half of 2015
CI
MOLOGEN AG Announces Managements Changes
CI
Mologen Holding AG’s Equity Buyback announced on June 7, 2010 has expired.
CI
Aarhus University Hospital Initiates MGN1703 Study in HIV Patients
CI
MOLOGEN AG Presents Data Supporting Administration Scheme of MGN1703 at ITOC-2 Conference 2015
CI
Mologen Reports Earnings Results for the Year 2014
CI
Mologen AG Presents Subgroup Analysis from Impact Study and Design of Pivotal Impala Trial
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MGNK Stock
  4. MGNK Stock
  5. News Mologen AG